...
首页> 外文期刊>Critical reviews in oncology/hematology >Toll-like receptors in lymphoid malignancies: Double-edged sword
【24h】

Toll-like receptors in lymphoid malignancies: Double-edged sword

机译:淋巴恶性肿瘤中的含量相似的受体:双刃剑

获取原文
获取原文并翻译 | 示例
           

摘要

Toll-like receptors (TLRs) are the best characterized pattern recognition receptors (PRRs), which play an essential role in the recognition of invading pathogens via specific microbial molecular motifs, comprising a bridge between the innate and adaptive immune responses. Toll-like receptors expression is determined in both normal immune cells and malignant cells, with a distinctive pattern compared to each other, rendering them plausible targets for cancer therapy. Improved molecular profiling of lymphoid malignancies may give new insights into pathogenesis of these cancers and pave the way for novel therapeutic agents, including TLR agonists. In the current review, we summarize the immunopathogenic roles of TLRs in B cell and T cell lymphomas, acute lymphoblastic leukemia, multiple myeloma, and chronic lymphocytic leukemia, as well as the results of studies on TLR ligands and their future implications to manage these hematologic malignancies.
机译:Toll样受体(TLR)是最佳表征的图案识别受体(PRRS),其在通过特异性微生物分子基质识别侵入病原体中起重要作用,包括先天和适应性免疫应答之间的桥梁。 在正常的免疫细胞和恶性细胞中,彼此相比,具有独特的模式,使其具有独特的图案,使其具有鲜明的癌症治疗靶标。 改善淋巴恶性肿瘤的分子分析可能会对这些癌症的发病机制产生新的见解,并为包括TLR激动剂的新型治疗剂铺平道路。 在目前的审查中,我们总结了TLRS在B细胞和T细胞淋巴瘤,急性淋巴细胞白血病,多发性骨髓瘤和慢性淋巴细胞白血病的免疫致病作用以及TLR配体的研究结果及其未来的管理这些血液学的影响 恶性肿瘤。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号